The variability of liver graft function and urinary 6β-hydroxycortisol to cortisol ratio during liver regeneration in liver transplant recipients

Clinical Transplantation

Volumn 18, Issue 2, 2004, Pages 124-129

  Kishino, Satoshi ^a   Ogawa, Maki ^b   Takekuma, Yoh ^b   Sugawara, Mitsuru ^b   Shimamura, Tsuyoshi ^b   Furukawa, Hiroyuki ^b   Todo, Satoru ^b   Miyazaki, Katsumi ^b  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cytochrome P450 3A4 (CYP3A4); Liver transplant recipient; Tacrolimus; Urinary 6 OHF F ratio

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 3A4; HYDROCORTISONE; TACROLIMUS;

ADULT; ARTICLE; CASE REPORT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; GRAFT REJECTION; HUMAN; HYDROCORTISONE URINE LEVEL; LIVER REGENERATION; LIVER TRANSPLANTATION; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; STATISTICAL SIGNIFICANCE; URINALYSIS; VOLUNTEER;

ADULT; BIOLOGICAL MARKERS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER; LIVER REGENERATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS;

EID: 1642483710     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1399-0012.2003.00133.x     Document Type: Article

References (32)

1. Inomata Y, Tanaka K, Egawa H et al. The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. Transplantation 1996: 61: 247.
2. Fukatsu S, Yano I, Igaarashi T et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol 2001: 57: 479.
3. Kronbach T, Fisscher V, Meyer UA. Cyclosporine metabolism in human liver: Identification of a cytochrome P450II gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988: 43: 630.
4. Sattler M, Guengerich FP, Yun CH, Christinas U, Sewing KF. Cytochrome P4503 A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992: 20: 753.
5. Shimada T, Yanazaki H, Mimura M, Inui Y, Guegerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994: 270: 414.
6. Lemoine A, Azoula YD, Dennison A et al. FK 506 renal toxicity and lack of detectable cytochrome P-450 3A in the liver graft of a patient undergoing liver transplantation. Hepatology 1994: 20: 1472.
7. Guengerich FP. Characterization of human cytochrome P-450 enzymes. FASEB J 1992; 6: 745.
8. Gao L, Ramzam I, Baker AB. Potential use of pharmacological markers to quantitatively assess liver function during liver transplantation surgery. Anaesth Intensive Care 2000: 28: 375.
9. Frey G, Pottecher T, Calon B et al. Early assessment of transplanted liver function: Lignocaine clearance test (MEGX). Eur J Anaesthesiol 1997: 14: 397.
10. Jalan R, Plevris JN, Jalan AR, Finlayson ND, Hayes PC. A pilot study of indocyanine green clearance as an early predictor of graft function. Transplantation 1994: 58: 196.
11. Heidecke CD, Martin WG, Muller DF et al. Acute liver allograft rejection and liver function: Quantitative evalution using the [14C] aminopyrine breath test. Transplant Proc 1993: 25: 2640.
12. Watkins PB. Noninvasive tests of CYP3A enzyme. Pharmacogenetics 1994: 4: 171.
13. Wilkinson GR. Cytochrome P450 (CYP3A) metabolism: Prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996: 24: 475.
14. Gred C, Rouillon JM, Pichard L et al. The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 1989: 28: 373.
15. Homma M, Beckerman K, Hayashi S et al. Liquid chromatographic determination of urinary 6β-hydroxycortisol to assess cytochrome p-450 3A activity in HIV-positive pregnant women. J Pharm Biomed Anal 2000: 23: 629.
16. Venkataramanan R, Jain A, Cado E et al. Pharmacokinetics of FK506: Preclinical and clinical studies. Transplant Proc 1990: 22(Suppl. 1): 52.
17. Venkataramanan R, Warty VS, Zemaitis MA et al. Biopharmaceutical aspects of FK506. Transplant Proc 1987: 19(Suppl. 6): 30.
18. Iwasaki K, Shiraga T, Nagase K et al. Pharmacokinetic study of FK506 in the rat. Transplant Proc 1991: 23: 2757.
19. Nakazawa Y, Chisuw AH, Ikegami T et al. Relationship between in vivo FK506 clearance and in vitro 13-demethylation activity in living-related liver transplantation. Transplantation 1998: 66: 1089.
20. Schmidt LE, Olsen AK, Stentoft K et al. Early postoperative erythromycin breath test correlates with hepatic cytochrome P-4503A activity in liver transplant recipients. Clin Pharmacol Ther 2001: 70: 446.
21. Thummel KE, Shen DD, Podoll TD et al. Use of midazolam as a human cytochrome P-4503A probe: I. In vitro-in vivo correlation in liver transplant patients. J Pharmacol Exp Ther 1994: 271: 549.
22. Thummel KE, Shen DD, Podoll TD et al. Use of midazolam as a human cytochrome P-4503A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994: 271: 557.
23. Burstein AH, Reiss WG, Kantor E, Anderson GD. Cytochrome P450 3A4 activity in premenopausal and postmenopausal women, based on 6β-hydroxycortisol/cortisol ratio. Pharmacotherapy 1998: 18: 1271.
24. Kovacs SJ, Martin DE, Everitt DE, Patterson SD, Jorkasky DK. Urinary 6β-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations. Clin Pharmacol Ther 1998: 63: 617.
25. Boulton DW, Arnaud P, Devane CL. A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio. Br J Clin Pharmacol 2001: 51: 350.
26. Watkins PB, Turfeon DK, Saenger P et al. Comparison of urinary 6-β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 1992: 52: 265.
27. Powis G, Jardine I, Van Dyke R et al. Foreign compound metabolism studies with human liver obtained as surgical waste. Relation to donor characteristics and effects of tissue storage. Drug Metab Dispos 1988: 16: 582.
28. Abu-Elmagd KM, Fung JJ, Alessiani M et al. Strategy of FK506 therapy in liver transplant patients: Effect of graft function. Transplant Proc 1991: 23: 2771.
29. Kinirons MT, O'shea D, Downing T et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993: 54: 621.
30. Kinirons MT, O'shea D. Kimm PB et al. Failure of erythromycin breath test to correlate with midazolam clearance as probe of cytochrome P4503A. Clin Pharmacol Ther 1999: 66: 224.
31. Yasui-furukori N, Kondo T, Kubota T et al. No correlations between the urinary ratio of 6β-hydroxycortisol to free cortisol and pharmacokinetics of alprazolam. Eur J Clin Pharmacol 2001: 57: 285.
32. Horsman Y, Desager JP, Havengt C. Absence of CYP3A genetic polymorphism assessed by urinary excretion of 6β-hydroxycortisol in 102 healthy subjects on rifampicin. Pharmacol Toxicol 1992: 71: 258.